Picture of OptiBiotix Health logo

OPTI OptiBiotix Health News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

REG - OptiBiotix Health - Result of Meeting <Origin Href="QuoteRef">OPTIO.L</Origin>

RNS Number : 9408C
OptiBiotix Health PLC
25 January 2018

25 January 2018

OptiBiotix Health plc

("OptiBiotix"orthe "Company")

Result of GM

OptiBiotixHealthplc(AIM: OPTI),alifesciencesbusinessdevelopingcompoundstotackleobesity,high

cholesterolanddiabetes, announces that at the General Meeting held earlier today, all resolutions were duly passed.

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner


finnCap (Broker)

Tel: 020 7220 0500

Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)


Tony Quirke (Corporate Broking)




Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.


This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMLLFSLLEIEFIT

Recent news on OptiBiotix Health

See all news